Asia Pacific Cancer Monoclonal Antibodies Market Research Report – Segmented By Application, Type, Conjugated Cancer Therapies & Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore and Rest of APAC) - Industry Analysis on Size, Share, Trends & Growth Forecast (2024 to 2029)

Updated On: January, 2024
ID: 160
Pages: 145

APAC Cancer Monoclonal Antibodies Market Size (2024 to 2029)

The size of the Cancer Monoclonal Antibodies Market in the Asia Pacific was valued at USD 8.57 billion in 2024 and is forecasted to be a USD 15.78 Billion market by 2029 with a tremendous growth rate  CAGR 13%.

Increasing incidences of cancer diseases is a key driving factor for growth in the Asia Pacific. Rising awareness over the availability of several treatment procedures for cancer disease is another attribute elevating the demand of the cancer monoclonal antibodies market in this region. Favorable conditions from the government to manufacture quality medicines for cancer patients at affordable prices are expanding the market shares. Adopting a sedentary lifestyle and changes in food habits also fuelled the demand for the cancer monoclonal antibodies market in the Asia Pacific.

However, the government's stringent rules and regulations in approving new drugs are slowly inhibiting the demand of the market. People in rural areas are unaware of cancer treatment procedures, which is a big challenging factor for market players. Lack of standardization is also to impact negatively on the growth of the market in the Asia Pacific. The dearth of skilled people in manufacturing quality drugs with the latest technology in undeveloped countries limits the growth rate of the cancer monoclonal antibodies market.

Growth opportunities for the market lie in the growing support from both private and public organizations through funds. The launch of innovative techniques with the latest technologies to treat cancer is expanding the market shares in the Asia Pacific.

This research report on the Asia Pacific Cancer Monoclonal Antibodies Market has been segmented and sub-segmented into the following categories:

By Application: 

  • Liver
  • Breast
  • Blood
  • Brain
  • Hodgkin’s And Non-Hodgkin’s Lymphoma
  • Colorectal
  • Leukemia
  • Others

By Type: 

  • Murine Antibodies
  • Chimeric & Humanised Antibodies
  • Fully Humanized Antibodies

By Conjugated Cancer Therapies: 

  • Immunoliposome
  • Radioimmunotherapy
  • Immunocytokines
  • Others

By Country: 

  • India
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Thailand
  • Malaysia
  • Vietnam
  • Philippines
  • Indonesia
  • Singapore
  • Rest of APAC

Regionally, India, and China are the major countries contributing to the highest shares for the market. Constant economic growth and the increasing geriatric population are two factors propelling the demand of the market. Japan and Australia are holding significant shares next to India and China by manufacturing quality drugs and taking steps to improve the treatment procedures in hospitals with the latest technology. The rest of the Asia Pacific is to have significant growth opportunities in foreseen years with the government's rising support.

Prominent companies dominating the APAC Cancer Monoclonal Antibodies Market profiled in this report are Amgen, Genmab, Briston Myers Squibb, GlaxoSmithKline, Eli Lilly, Roche, Immunogen, Seattle Genetics, Novartis & Spectrum Pharmaceuticals.

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample